Canada · Delayed Price · Currency is CAD NurExone Biologic Statistics
Total Valuation
TSXV:NRX has a market cap or net worth of CAD 49.70 million. The enterprise value is 47.69 million.
| Market Cap | 49.70M |
| Enterprise Value | 47.69M |
Important Dates
The next estimated earnings date is Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:NRX has 92.05 million shares outstanding. The number of shares has increased by 21.07% in one year.
| Current Share Class | 92.05M |
| Shares Outstanding | 92.05M |
| Shares Change (YoY) | +21.07% |
| Shares Change (QoQ) | +4.28% |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | n/a |
| Float | 87.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 17.79 |
| P/TBV Ratio | 17.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.23, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.23 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -182.29 |
Financial Efficiency
Return on equity (ROE) is -390.11% and return on invested capital (ROIC) is -233.39%.
| Return on Equity (ROE) | -390.11% |
| Return on Assets (ROA) | -150.84% |
| Return on Invested Capital (ROIC) | -233.39% |
| Return on Capital Employed (ROCE) | -267.73% |
| Weighted Average Cost of Capital (WACC) | 6.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.27% in the last 52 weeks. The beta is 0.35, so TSXV:NRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -20.27% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 43.53 |
| Average Volume (20 Days) | 15,512 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.91M |
| Pretax Income | -9.03M |
| Net Income | -9.03M |
| EBITDA | -8.67M |
| EBIT | -8.91M |
| Earnings Per Share (EPS) | -0.11 |
Balance Sheet
The company has 2.11 million in cash and 94,918 in debt, with a net cash position of 2.01 million or 0.02 per share.
| Cash & Cash Equivalents | 2.11M |
| Total Debt | 94,918 |
| Net Cash | 2.01M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 2.79M |
| Book Value Per Share | 0.03 |
| Working Capital | 1.32M |
Cash Flow
In the last 12 months, operating cash flow was -6.65 million and capital expenditures -34,897, giving a free cash flow of -6.68 million.
| Operating Cash Flow | -6.65M |
| Capital Expenditures | -34,897 |
| Depreciation & Amortization | 235,710 |
| Net Borrowing | -37,658 |
| Free Cash Flow | -6.68M |
| FCF Per Share | -0.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:NRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.07% |
| Shareholder Yield | -21.07% |
| Earnings Yield | -18.18% |
| FCF Yield | -13.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |